Paula Ragan, PhD
CEO and President
Dr. Ragan has been X4’s President and Chief Executive Officer and a member of the X4 Board of Directors since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. Prior to founding X4, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the company’s business development activities. Prior to that, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed post-doctoral studies at Harvard Medical School. Read More
Adam Mostafa
Chief Financial Officer
Mr. Mostafa has served as X4’s Chief Financial Officer since September 2018. Prior to joining X4, Mr. Mostafa served as chief financial officer of Abpro Corporation, a biotechnology company focused on antibody therapeutics. Prior to that, Mr. Mostafa was a managing director in the healthcare investment banking group at Cantor Fitzgerald, and was a senior banker in the healthcare investment banking group at Needham & Company. Prior to that, Mr. Mostafa was a vice president in the investment banking group at CRT Capital Group, and was a portfolio management associate in the global stock selection group at AQR Capital. He began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Mr. Mostafa earned an A.B. in Economics from Brown University. Read More
Derek Meisner, J.D.
General Counsel
Derek Meisner, J.D., serves as General Counsel at X4. Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance. Most recently, Mr. Meisner held the role of General Counsel at Genocea Biosciences, a Cambridge-based, publicly traded, clinical-stage biopharmaceutical company. Prior to Genocea, he served as General Counsel of multiple Boston-based financial services firms, including prominent life science investor RA Capital Management, and he was previously a partner at the international law firm K&L Gates and Branch Chief in the Division of Enforcement of the U.S. Securities and Exchange Commission. Mr. Meisner holds a B.A. from the University of Michigan and a J.D. from the Washington College of Law at American University. Read More
Mary DiBiase, PhD
Senior Vice President, Technical Operations and Quality
Dr. DiBiase is the Senior Vice President of Technical Operations and Quality at X4. She has more than 20 years of drug development and technical operations experience in both large and small organizations holding leadership roles in technical development, product operations and program management. Prior to X4 she was VP Technical Operations and Program Management at Epirus Biopharmaceuticals, a small biosimilar company working to expand access to biosimilar products across the globe. Other professional roles include VP Product Operations, Specialty Care Business Unit for Pfizer Global Supply, and multiple positions of increasing responsibility at Biogen including Sr Director CMC Management, Program Executive for Avonex® and Associate Director Pharmaceutical Science and Technology. Dr. DiBiase received her PhD from the University of Rhode Island and her B.Pharm. from the University of London. Read More
Ronny Mosston, MBA
Senior Vice President of Human Resources
Ms. Mosston is the Senior Vice President of Human Resources at X4. She has served in leadership positions in Human Resources and Patient Advocacy/Engagement at several prominent biotechnology and life sciences companies for more than 20 years, spanning disease areas such as oncology, rare disease and infertility. In addition to senior positions held at Millennium Pharmaceuticals, Takeda, and OvaScience, Ms. Mosston has provided expert consulting to executive teams at both public and private biotechnology companies to help build patient engagement and human resources strategies that align with business and cultural goals. Prior to working in life sciences, she was a Partner and Chief Operating Officer of a Boston based staffing and executive search company which became publicly traded and was acquired by a global Human Resources Consulting company. Ms. Mosston serves on the Dana Farber Patient and Family Advisory Council and previously served as its co-chair. She sits on the Executive Committee of the Joe Andruzzi Cancer Foundation, is a founding member of the MassBIO Patient Advocacy Committee and a member of the Healthcare Businesswomen’s Association (HBA). Ms. Mosston received her BS in Biology and her MBA, in Human Resources Management from Boston University. Read More
Nic Scalfarotto, DVM
Senior Vice President, Regulatory Affairs
Dr. Scalfarotto is the Senior Vice President, Regulatory Affairs at X4. With over 25 years of experience at biopharmaceutical companies and clinical research organizations, he has held executive roles covering multiple stages of development including solutions for treating rare and ultra-rare diseases. His experience has spanned diverse development programs covering small molecules, novel biologics, biosimilars, bio-betters, follow-on biologics, imaging agents and combination products. Initially focused on preclinical development, his regulatory career evolved in small and large corporate settings including PAREXEL, Millennium, Bristol-Myers, Eurand, Momenta, EMD Serono and GE Healthcare. He has been responsible for global regulatory development, in multiple therapeutic areas including Cardiology, Oncology, Immunology, Endocrinology, Gastroenterology, Dermatology, Rheumatology, Neurology and Biomarker development, as well as, support of licensing activities. Most recently, he held the position of Senior Vice President, Regulatory Affairs at Aegerion Pharmaceuticals, focusing on the development of products targeting rare metabolic diseases. Additionally in prior positions at three CROs (MetTrials, Chrysalis and Oread), Dr. Scalfarotto held General Management positions with encompassed such responsibilities as strategic and tactical planning, finance, operations, business development, regulatory affairs, quality assurance, information systems and facilities planning. Dr. Scalfarotto holds an undergraduate degree in biological sciences from Seton Hall University and a degree in Veterinary Medicine from the University of Bologna. Read More
Carrie Melvin, MBA
Senior Vice President, Development Operations
Ms. Melvin is Senior Vice President of Development Operations at X4. She has more than 20 years of experience and has led Global Clinical Operations for top pharmaceutical and biotechnology companies, with extensive experience in oncology global drug development, including clinical trial conduct, close-out, submissions, inspections and approvals. Prior to joining X4, Ms. Melvin was the Vice President of Global Clinical Sciences and Delivery for Oncology at GSK and Vice President of Global Clinical Operations at TESARO (acquired by GSK). Prior to that, she was Vice President of Global Clinical Operations at Kura Oncology. Ms. Melvin has also held positions of Director of Global Development Project Management at EMD Serono and Director of Clinical Operations at Millennium: The Takeda Oncology Company. Ms. Melvin began her pharmaceutical career at Pfizer, Inc. Prior to joining the pharmaceutical industry, Ms. Melvin spent 3 years as a Registered Nurse at a community hospital in Connecticut. Ms. Melvin received her BSN with highest distinction from University of Rhode Island and her MBA from Boston University, School of Management. Read More
Shariq Ali, PhD
Vice President, Medical Affairs
Dr. Ali is Vice President of Medical Affairs at X4 Pharmaceuticals. He has more than a decade of experience leading teams to launch transformative therapies across a diverse set of disease areas, including rare diseases and rare hematological disorders. Previously, Shariq served as VP of Medical Affairs at Wave Life Sciences, where he helped build and establish the medical affairs organization, to prepare for launching a potential therapy for Duchenne muscular dystrophy (DMD). In addition, Dr. Ali spent several years leading various aspects of the medical function for Sanofi Genzyme’s Rare Diseases and Rare Blood Disorder franchises, and prior to that, he was part of the medical team at Alexion Pharmaceuticals responsible for launching Soliris for patients living with Paroxysmal Nocturnal Hemoglobinuria (PNH). Dr. Ali has also held faculty and department chair appointments at A&M Schwartz College of Pharmacy & Health Sciences, Long Island University, and the Touro College of Pharmacy. He received his PhD in pharmacology from New York Medical College and completed his post-doctoral training at Cornell University Medical College. Read More
Brian Bowersox
Vice President, Finance
Mr. Bowersox has more than 15 years of progressive experience in finance and accounting functions, leveraging capital allocation and business transformation initiatives while helping to maximize profitability and enterprise value. Mr. Bowersox previously served in a similar role as a corporate controller at a Massachusetts-based life sciences company, Abpro, where he provided strategic financial counsel to corporate management and business partners across all functions of the organization, including business development valuations, systems implementation and optimization, annual planning and projections and effective accounting policies and principles. He received his Master’s in Business Administration at Southern New Hampshire University and his Bachelor’s in Accounting at Bryant University. Read More
Michele Rhee, MPH, MBA
Vice President, Patient Affairs and Advocacy
Michele Rhee is Head of Patient Affairs and Advocacy of X4 Pharmaceuticals. She has more than a decade of experience leading patient affairs and advocacy across pharmaceutical and nonprofit industries. Michele is embedded within the rare disease and oncology patient communities through both her extensive professional work and her personal experience with a cancer diagnosis at age 20 and rare disease diagnosis at age 21. Partnering with these communities, she has led patient interviews/advisory boards and represented the patient perspective, which has directly informed trial design, patient support services, and disease education programs, among other efforts. Michele previously served as Head of Patient Affairs at Enzyvant where she helped build the Patient Affairs function, developing and maintaining both global patient advisor and advocacy partnerships across disease areas. During her time there, the company was nominated for a Global Genes 2019 RARE Champions of Hope award, in part, due to its expanding efforts in Patient Advocacy. Prior to her work at Enzyvant, Michele served as Global and R&D Patient Advocacy Lead at Takeda Oncology, Head of Global Patient Affairs at Bluebird Bio, and Director of both Strategic Initiatives and Program Initiatives at the National Brain Tumor Society. In addition, Michele has served as Chair of the MassBio Patient Advocacy Roundtable since 2017, is a founding board member for Costs of Care, an organization dedicated to helping clinicians and health systems deliver better care at lower cost, and was named a 2019 PharmaVOICE 100 honoree. Michele received her MPH from Yale School of Public Health and her MBA from Yale School of Management. Read More

X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.